NCT04629729 2026-03-19
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
Fate Therapeutics
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
Celgene
Chinese PLA General Hospital
Stanford University